Last edition
News about "phase 3 INShore study"
Chugai Pharmaceutical Files Japan Approval for Gazyva in Idiopathic Nephrotic Syndrome
Chugai Pharmaceutical files a regulatory application in Japan for Gazyva to treat Idiopathic Nephrotic Syndrome (INS), based on phase 3 INShore study results.
Phase 3 INShore Study | 15/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members